sniffing mushrooms? – Israeli biopharmaceutical company makes psilocybin nasal spray

Israel is about to unveil another breakthrough treatment for mental illness. This latest approach aims to solve certain mental health conditions with small doses of psilocybin.

Madrigal Mental Care is an Israeli biopharmaceutical company behind this novel modern medical treatment. The company said it would showcase the developed nanotechnology at the Biomed Israel 2022 event this week. According to the press release, the treatment uses a nasal spray to prevent and treat symptoms of post-traumatic stress disorder (PTSD). The pharmaceutical event took place at the David Intercontinental Hotel in Tel Aviv, Israel.

The Biomed Israel event is held to honor the technology and life sciences industry. At least 5,000 people have attended the past events of this body. From this lot over 1,000 participants are international participants from over 40 countries

The latest treatment

Israel’s Madrigal Mental Care revealed that the nasal spray system is an effective nose-to-brain delivery system. With this technique, the user gets the encapsulated psilocybin molecule (psychedelic substance) that is absorbed into the bloodstream almost instantly.

Professor Amnon Sintov from the Department of Biomedical Engineering at Ben-Gurion University of the Negev (BGU) made this incredible nanotechnology invention. The spray can administer other drugs such as MDMA, ketamine, mescaline, and other psychedelics. Sintov works under BGU Technology Licensing (i.e. BGU’s technology transfer company).

Professor Amnon Sintov said that many studies have examined the benefits of using psychedelics to treat mental disorders such as depression, anxiety, addiction, obsessive-compulsive disorder (OCD) and PTSD. He says most of these studies have provided evidence that psychedelics are effective.

Psychedelics have an intense effect on the human brain. Sintov pointed out that safe and precise dosing of psychedelics is the only way to realize their therapeutic benefits.

Sintov explained that his brilliant innovation would ensure precise drug doses are fully encapsulated in nanoparticles. These tiny particles are then sent to the brain through an intranasal spray. He added that the technique is fast, safe and efficient.

Research on psilocybin continues

Recently, more researchers are basing their studies on psilocybin’s effectiveness in resolving depression and PTSD symptoms. They are also investigating the use of psychedelics for end-of-life care.

Psilocybin is a proven 5-HT2A agonist. This suggests that the drug would produce multiple therapeutic effects in multiple areas. Also note that the brain’s cortex has numerous 5-HT2A receptors that influence creativity, reflection, and thinking.

Madrigal Mental Care co-founder and chairman David Gabay said the novel technology would quickly deliver prescribed doses of psychoactive substances. He stressed that the nanoparticles are biodegradable. Compared to other treatments, this offers the client better stability and higher chances of getting accurate results.

Another in vitro study conducted at BGU’s Institute of Biochemistry and Pharmacology observed that inflamed brain cell cultures show improvement when administered as nanoparticles. One of the on-site researchers, Professor Shimon Ben-Shabat, said the team would start preclinical studies in weeks. He explained that the proposed study would be conducted using rodents. At the end of the study, researchers hope to have safety and efficacy approvals to get clinical trials underway by next year.

According to Ben-Shabat and other scientists on board the investigative study, this latest nanotechnology technique for psychedelics delivery may advance the entire field of psychedelics-based treatments. The success of this treatment program in the preclinical and clinical trials would benefit thousands, if not millions, of people worldwide suffering from acute or chronic mental illnesses, particularly depression and post-traumatic stress disorder (PTSD).

A growing need for alternative therapies

The medical sector is at a crossroads where patients have become more tolerant of the available conventional drugs that are being administered. The industry is at a point where it needs multiple treatment options, including unconventional strategies.

Increasing research into psilocybin and cannabis is putting the industry on the right track. When conventional therapies fail, medical professionals could turn to alternative therapies such as the use of cannabis or psilocybin-derived drugs. The drugs would be made in such a way that users could use them and see results as quickly as possible.

The Senior Vice President of Business Development, BioPharma, Dr. Galit Mazoon Perlmutter mentioned that the medical industry desperately needs better treatments to help people suffering from PTSD and other mental disorders. Perlmutter announced that BGU Technologies has applied to file the nanotechnology intranasal spray as their patent. Their discovery could be one of the most important breakthroughs in alternative medical treatments this decade. No one can deny that top scientists are working on it at Ben Gurion University.

Funnily enough, this topic used to be a regular discussion point on inline forums like Reddit. Today, the world is keen to learn the benefits that psilocybin microsoding could bring. Patients suffering from PTSD, depression and other mental disorders can now look forward to breakthrough treatment.

In the meantime…

In the United States, the FDA recently approved an esketamine nasal spray. Available reports claim that these nasal sprays are being used in various clinics in all legal regions of the country. A few months ago, a New York psychiatrist observed that mushrooms significantly reduced the suffering of cancer patients. New York University says it now has a learning module to further explore the therapeutic benefits and side effects of mushrooms.

Back in Israel, the country has always been an avid supporter of cannabis treatments. In fact, Israel is home to a wide variety of cannabis-related medicinal products. The country’s support for advanced research into cannabis and psychedelics gives citizens hope that these alternative treatments will soon be available.

Last word

Israel’s healthcare sector is one of the best in the world, and the government continues to allocate enough funds to conduct experiments so the healthcare sector can thrive. Biomed Conference organizers have announced that they are preparing for a much larger attendance at the next event. They also said they would extend the invitations to members from other sectors. According to The Times of Israel, the next event would focus on cancer treatment and organic food. Who knows what novel discovery would be revealed by then.

WEED SCIENCE, READ MORE..

TO OBTAIN CANNABIS LIQUID? BIG BREAKTHROUGH OR NO BIG DEAL?